Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
7.86M
-
Shares change
-
-5.85M
-
Total reported value, excl. options
-
$17.3M
-
Value change
-
-$14.1M
-
Put/Call ratio
-
0.57
-
Number of buys
-
20
-
Number of sells
-
-49
-
Price
-
$2.20
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q2 2022
87 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q2 2022.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.86M shares
of 66.6M outstanding shares and own 11.81% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.76M shares), Artal Group S.A. (750K shares), RENAISSANCE TECHNOLOGIES LLC (728K shares), Laurion Capital Management LP (722K shares), GEODE CAPITAL MANAGEMENT, LLC (412K shares), MILLENNIUM MANAGEMENT LLC (394K shares), TWO SIGMA ADVISERS, LP (335K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (319K shares), CHARTWELL INVESTMENT PARTNERS, LLC (297K shares), and DEUTSCHE BANK AG\ (224K shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.